Skip to main content

Articles

Page 5 of 34

  1. Although hypertension is a critical risk factor for dementia, the association between primary aldosteronism (PA) and dementia has been scarcely reported. We aimed to investigate whether the risk of dementia in...

    Authors: Namki Hong, Kyoung Jin Kim, Min Heui Yu, Seong Ho Jeong, Seunghyun Lee, Jung Soo Lim and Yumie Rhee
    Citation: Alzheimer's Research & Therapy 2023 15:136
  2. Neuropsychiatric symptoms due to Alzheimer’s disease (AD) and mild cognitive impairment (MCI) can decrease quality of life for patients and increase caregiver burden. Better characterization of neuropsychiatri...

    Authors: Grace J. Goodwin, Stacey Moeller, Amy Nguyen, Jeffrey L. Cummings and Samantha E. John
    Citation: Alzheimer's Research & Therapy 2023 15:135
  3. Obstructive sleep apnoea (OSA) has a high prevalence in patients with Alzheimer’s disease (AD). Both conditions have been shown to be associated with lipid dysregulation. However, the relationship between OSA ...

    Authors: Farida Dakterzada, Iván D. Benítez, Adriano Targa, Anna Carnes, Montse Pujol, Mariona Jové, Olga Mínguez, Rafi Vaca, Manuel Sánchez-de-la-Torre, Ferran Barbé, Reinald Pamplona and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2023 15:134
  4. Alzheimer’s dementia (AD) is associated with electroencephalography (EEG) abnormalities including in the power ratio of beta to theta frequencies. EEG studies in mild cognitive impairment (MCI) have been less ...

    Authors: Hamed Azami, Christoph Zrenner, Heather Brooks, Reza Zomorrodi, Daniel M. Blumberger, Corinne E. Fischer, Alastair Flint, Nathan Herrmann, Sanjeev Kumar, Krista Lanctôt, Linda Mah, Benoit H. Mulsant, Bruce G. Pollock and Tarek K. Rajji
    Citation: Alzheimer's Research & Therapy 2023 15:133
  5. Subjective cognitive decline (SCD) is a risk factor for Alzheimer’s disease (AD); however, the rates of cognitive decline are variable according to underlying pathologies and biomarker status. We conducted an ...

    Authors: Yun Jeong Hong, SeongHee Ho, Jee Hyang Jeong, Kee Hyung Park, SangYun Kim, Min Jeong Wang, Seong Hye Choi and Dong Won Yang
    Citation: Alzheimer's Research & Therapy 2023 15:132
  6. The paradigm shift towards earlier Alzheimer’s disease (AD) stages and personalized medicine creates new challenges for clinician-patient communication. We conducted a survey among European memory clinic profe...

    Authors: Heleen M. A. Hendriksen, Aniek M. van Gils, Argonde C. van Harten, Tobias Hartmann, Francesca Mangialasche, Anita Kamondi, Miia Kivipelto, Hanneke F. M. Rhodius-Meester, Ellen M. A. Smets, Wiesje M. van der Flier and Leonie N. C. Visser
    Citation: Alzheimer's Research & Therapy 2023 15:131
  7. There are few updated studies on the prevalence and management of Alzheimer’s disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagno...

    Authors: Javier Olazarán, Cristóbal Carnero-Pardo, Juan Fortea, Pascual Sánchez-Juan, Guillermo García-Ribas, Félix Viñuela, Pablo Martínez-Lage and Mercè Boada
    Citation: Alzheimer's Research & Therapy 2023 15:130
  8. In order to utilize polygenic risk scores (PRSs) for Alzheimer’s disease (AD) in a meaningful way, influential factors (i.e. training set) and prediction across groups such as APOE e4 (APOE4) genotype as well as ...

    Authors: Hannah Stocker, Kira Trares, Léon Beyer, Laura Perna, Dan Rujescu, Bernd Holleczek, Konrad Beyreuther, Klaus Gerwert, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:129
  9. With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary popula...

    Authors: Soeren Mattke, Hankyung Jun, Emily Chen, Ying Liu, Andrew Becker and Christopher Wallick
    Citation: Alzheimer's Research & Therapy 2023 15:128
  10. We aimed to quantify the identification of mild cognitive impairment and/or Alzheimer’s disease using olfactory-stimulated functional near-infrared spectroscopy using machine learning through a post hoc analys...

    Authors: Jaewon Kim, Hayeon Lee, Jinseok Lee, Sang Youl Rhee, Jae Il Shin, Seung Won Lee, Wonyoung Cho, Chanyang Min, Rosie Kwon, Jae Gwan Kim and Dong Keon Yon
    Citation: Alzheimer's Research & Therapy 2023 15:127
  11. Traumatic encephalopathy syndrome (TES) is a clinical phenotype sensitive but non-specific to underlying chronic traumatic encephalopathy (CTE) neuropathology. However, cognitive symptoms of TES overlap with A...

    Authors: Breton M. Asken, Jeremy A. Tanner, Leslie S. Gaynor, Lawren VandeVrede, William G. Mantyh, Kaitlin B. Casaletto, Adam M. Staffaroni, Corrina Fonseca, Ranjani Shankar, Harli Grant, Karen Smith, Argentina Lario Lago, Haiyan Xu, Renaud La Joie, Yann Cobigo, Howie Rosen…
    Citation: Alzheimer's Research & Therapy 2023 15:126
  12. People with intellectual disability (ID) without Down syndrome (DS) are presumed to be at higher risk of developing dementia due to their lower baseline cognitive reserve. We aimed to determine the prevalence ...

    Authors: Shintaro Takenoshita, Seishi Terada, Tomokazu Inoue, Taku Kurozumi, Norihito Yamada, Ryozo Kuwano and Shigeru Suemitsu
    Citation: Alzheimer's Research & Therapy 2023 15:125
  13. Alzheimer’s disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40 ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of disease. However, these markers do not fully...

    Authors: Silvia Paciotti, Anna Lidia Wojdała, Giovanni Bellomo, Andrea Toja, Elena Chipi, Sander R. Piersma, Thang V. Pham, Lorenzo Gaetani, Connie R. Jimenez, Lucilla Parnetti and Davide Chiasserini
    Citation: Alzheimer's Research & Therapy 2023 15:124
  14. Previous studies challenge the impact of obstructive sleep apnea (OSA) once patients are diagnosed with Alzheimer’s disease (AD). Nevertheless, OSA recognizably disrupts sleep, and relevant associations betwee...

    Authors: Adriano D. S. Targa, Iván D. Benítez, Anna Moncusí-Moix, Farida Dakterzada, Olga Minguez, Rafaela Vaca, Mireia Dalmases, Manuel Sanchez-de-la-Torre, Ferran Barbé and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2023 15:123
  15. Alzheimer’s disease (AD) is a common age-related neurodegenerative disease in the central nervous system and is the primary cause of dementia. It is clinically characterized by the memory impairment, aphasia, ...

    Authors: Jia-jia Liu, Yun-fan Long, Peng Xu, Hai-dong Guo and Guo-hong Cui
    Citation: Alzheimer's Research & Therapy 2023 15:122
  16. Gene expression is dysregulated in Alzheimer’s disease (AD) patients, both in peripheral blood and post mortem brain. We investigated peripheral whole-blood gene (co)expression to determine molecular changes p...

    Authors: Emma S. Luckett, Magdalena Zielonka, Amine Kordjani, Jolien Schaeverbeke, Katarzyna Adamczuk, Steffi De Meyer, Koen Van Laere, Patrick Dupont, Isabelle Cleynen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2023 15:121
  17. Emerging difficulty performing cognitively complex everyday tasks, or ‘instrumental activities of daily living’ (IADL) may be an early clinical sign of Alzheimer’s disease (AD). We aimed to investigate how cha...

    Authors: Mark A. Dubbelman, Kayden J. Mimmack, Emily H. Sprague, Rebecca E. Amariglio, Patrizia Vannini and Gad A. Marshall
    Citation: Alzheimer's Research & Therapy 2023 15:120
  18. The APOEε4-promoted risk of Alzheimer’s disease (AD) is lower in Black/African-Americans (B/AAs), compared to non-Hispanic whites (NHWs). Previous studies reported lower plasma apolipoprotein E (apoE) levels in N...

    Authors: Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C. Howell, William T. Hu, Kim Kultima and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2023 15:119

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:160

  19. In the ongoing effort to discover treatments for Alzheimer’s disease (AD), there has been considerable focus on investigating the use of repurposed drug candidates. Mining of electronic health record data has ...

    Authors: Eric Hu, Tong Shu Li, Nathan E. Wineinger and Andrew I. Su
    Citation: Alzheimer's Research & Therapy 2023 15:118
  20. Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiolog...

    Authors: Patricia Diaz-Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:117

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:177

  21. Authors: Janne Marieke Herden, Peter Hermann, Isabel Schmidt, Kathrin Dittmar, Sezgi Canaslan, Luise Weglage, Sabine Nuhn, Corinna Volpers, Astrid Schlung, Stefan Goebel, Fabian Kück, Anna Villar‑Piqué, Christian Schmidt, Dirk Wedekind and Inga Zerr
    Citation: Alzheimer's Research & Therapy 2023 15:116

    The original article was published in Alzheimer's Research & Therapy 2023 15:106

  22. Alzheimer’s disease (AD) is caused by many intertwining pathologies involving metabolic aberrations. Patients with metabolic syndrome (MetS) generally show hyperglycemia and dyslipidemia, which can lead to the...

    Authors: Monika Renuka Sanotra, Shu-Huei Kao, Ching-Kuo Lee, Chun-Hsien Hsu, Wen-Chung Huang, Tsuei-Chuan Chang, Fang-Yu Tu, I-Uen Hsu and Yung-Feng Lin
    Citation: Alzheimer's Research & Therapy 2023 15:115
  23. Neuropsychiatric symptoms (NPS) are a core feature of most neurodegenerative and cerebrovascular diseases. White matter hyperintensities and brain atrophy have been implicated in NPS. We aimed to investigate t...

    Authors: Miracle Ozzoude, Brenda Varriano, Derek Beaton, Joel Ramirez, Sabrina Adamo, Melissa F. Holmes, Christopher J. M. Scott, Fuqiang Gao, Kelly M. Sunderland, Paula McLaughlin, Maged Goubran, Donna Kwan, Angela Roberts, Robert Bartha, Sean Symons, Brian Tan…
    Citation: Alzheimer's Research & Therapy 2023 15:114
  24. Genome-wide association studies (GWAS) have indicated moderate genetic overlap between Alzheimer’s disease (AD) and related dementias (ADRD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), n...

    Authors: Michael Wainberg, Shea J. Andrews and Shreejoy J. Tripathy
    Citation: Alzheimer's Research & Therapy 2023 15:113
  25. Alzheimer’s disease is a neurodegenerative disorder associated with the abnormal deposition of pathological processes, such as amyloid-ß and tau, which produces nonlinear changes in the functional connectivity...

    Authors: Mite Mijalkov, Dániel Veréb, Anna Canal-Garcia, Thomas Hinault, Giovanni Volpe and Joana B. Pereira
    Citation: Alzheimer's Research & Therapy 2023 15:112
  26. Dementia, one of the fastest-growing public health problems, is a cognitive disorder known to increase in prevalence as age increases. Several approaches had been used to predict dementia, especially in buildi...

    Authors: Michael Adebisi Fayemiwo, Toluwase Ayobami Olowookere, Oluwabunmi Omobolanle Olaniyan, Theresa Omolayo Ojewumi, Idowu Sunday Oyetade, Shannon Freeman and Piper Jackson
    Citation: Alzheimer's Research & Therapy 2023 15:111
  27. Frailty and dementia have a bidirectional relationship. However, frailty is rarely reported in clinical trials for dementia and mild cognitive impairment (MCI) which limits assessment of trial applicability. T...

    Authors: Heather Wightman, Terry J. Quinn, Frances S. Mair, Jim Lewsey, David A. McAllister and Peter Hanlon
    Citation: Alzheimer's Research & Therapy 2023 15:110
  28. The correlations between genetic risk for Alzheimer’s disease (AD) with comprehensive brain regions at a regional scale are still not well understood. We aim to explore whether these associations vary across d...

    Authors: Xiao-Yu He, Bang-Sheng Wu, Kevin Kuo, Wei Zhang, Qing Ma, Shi-Tong Xiang, Yu-Zhu Li, Zi-yi Wang, Qiang Dong, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:109
  29. Low body mass index (BMI) or underweight status in late life is associated with an increased risk of dementia or Alzheimer’s disease (AD). However, the relationship between late-life BMI and prospective longit...

    Authors: Seunghoon Lee, Min Soo Byun, Dahyun Yi, Min Jung Kim, Joon Hyung Jung, Nayeong Kong, Gijung Jung, Hyejin Ahn, Jun-Young Lee, Koung Mi Kang, Chul-Ho Sohn, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2023 15:108
  30. Chemokines, which are chemotactic inflammatory mediators involved in controlling the migration and residence of all immune cells, are closely associated with brain inflammation, recognized as one of the potent...

    Authors: Futao Zhou, Yangyan Sun, Xinhua Xie and Yushi Zhao
    Citation: Alzheimer's Research & Therapy 2023 15:107
  31. Rapidly progressive forms of Alzheimer’s disease (rpAD) are increasingly recognized and may have a prevalence of up to 30% of patients among all patients with Alzheimer’s disease (AD). However, insights about ...

    Authors: Janne Marieke Herden, Peter Hermann, Isabel Schmidt, Kathrin Dittmar, Sezgi Canaslan, Luise Weglage, Sabine Nuhn, Corinna Volpers, Astrid Schlung, Stefan Goebel, Fabian Kück, Anna Villar-Piqué, Christian Schmidt, Dirk Wedekind and Inga Zerr
    Citation: Alzheimer's Research & Therapy 2023 15:106

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:116

  32. Over recent years, increasing evidence suggests a causal relationship between neurofibrillary tangles (NFTs) formation, the main histopathological hallmark of tauopathies, including Alzheimer’s disease (AD), a...

    Authors: Carolina Bianchi, Beatriz Alvarez-Castelao, Álvaro Sebastián-Serrano, Caterina Di Lauro, Lucia Soria-Tobar, Annette Nicke, Tobias Engel and Miguel Díaz-Hernández
    Citation: Alzheimer's Research & Therapy 2023 15:105
  33. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:104

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  34. White matter hyperintensities, a neuroimaging marker of small-vessel cerebrovascular disease and apolipoprotein ε4 (APOE4) allele, are important dementia risk factors. However, APOE4 as a key effect modifier i...

    Authors: Ashwati Vipin, Dilip Kumar, See Ann Soo, Fatin Zahra Zailan, Yi Jin Leow, Chen Ling Koh, Adeline Su Lyn Ng, Kok Pin Ng and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2023 15:103
  35. The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics of brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may c...

    Authors: Anna M. de Kort, H. Bea Kuiperij, Lieke Jäkel, Iris Kersten, Ingeborg Rasing, Ellis S. van Etten, Sanneke van Rooden, Matthias J. P. van Osch, Marieke J. H. Wermer, Gisela M. Terwindt, Floris H. B. M. Schreuder, Catharina J. M. Klijn and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2023 15:102
  36. Increasing evidence links the gut microbiota (GM) to Alzheimer’s disease (AD) but the mechanisms through which gut bacteria influence the brain are still unclear. This study tests the hypothesis that GM and me...

    Authors: Moira Marizzoni, Peppino Mirabelli, Elisa Mombelli, Luigi Coppola, Cristina Festari, Nicola Lopizzo, Delia Luongo, Monica Mazzelli, Daniele Naviglio, Jean-Louis Blouin, Marc Abramowicz, Marco Salvatore, Michela Pievani, Annamaria Cattaneo and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2023 15:101
  37. Plasma amyloid-β (Aβ) peptides and tau proteins are promising biomarkers of Alzheimer’s disease (AD), not only for predicting Aβ and tau pathology but also for differentiating AD from other neurodegenerative d...

    Authors: Jingshan Chen, Xue Zhao, Wenyan Zhang, Tianxiang Zhang, Siting Wu, Jinghao Shao and Fu-Dong Shi
    Citation: Alzheimer's Research & Therapy 2023 15:100
  38. Cortical tau accumulation is a key pathological event that partly defines Alzheimer’s disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understand...

    Authors: Antoinette O’Connor, David M. Cash, Teresa Poole, Pawel J. Markiewicz, Maggie R. Fraser, Ian B. Malone, Jieqing Jiao, Philip S. J. Weston, Shaney Flores, Russ Hornbeck, Eric McDade, Michael Schöll, Brian A. Gordon, Randall J. Bateman, Tammie L. S. Benzinger and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2023 15:99
  39. Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...

    Authors: Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton and Suzanne B. Hendrix
    Citation: Alzheimer's Research & Therapy 2023 15:98
  40. White matter hyperintensities (WMH) in subjects across the Alzheimer’s disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just arterial hypertension—impacts WMH, which in...

    Authors: Jose Bernal, Stefanie Schreiber, Inga Menze, Anna Ostendorf, Malte Pfister, Jonas Geisendörfer, Aditya Nemali, Anne Maass, Renat Yakupov, Oliver Peters, Lukas Preis, Luisa Schneider, Ana Lucia Herrera, Josef Priller, Eike Jakob Spruth, Slawek Altenstein…
    Citation: Alzheimer's Research & Therapy 2023 15:97
  41. Carrying the apolipoprotein E (ApoE) Ɛ4 allele is associated with an increased risk of cerebral amyloidosis and late-onset Alzheimer’s disease, but the degree to which apoE glycosylation affects its developmen...

    Authors: Cristiana J. Meuret, Yueming Hu, Sabrina Smadi, Mikaila Ann Bantugan, Haotian Xian, Ashley E. Martinez, Ronald M. Krauss, Qiu-Lan Ma, Dobrin Nedelkov and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2023 15:96
  42. The purpose of this study was to evaluate cholesterol esterification and HDL subclasses in plasma and cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients.

    Authors: Marta Turri, Elisa Conti, Chiara Pavanello, Francesco Gastoldi, Marcella Palumbo, Franco Bernini, Vittoria Aprea, Francesca Re, Alberto Barbiroli, Davide Emide, Daniela Galimberti, Lucio Tremolizzo, Francesca Zimetti and Laura Calabresi
    Citation: Alzheimer's Research & Therapy 2023 15:95
  43. Neuropsychiatric symptoms (NPS) are prevalent in the early clinical stages of Alzheimer’s disease (AD) according to proxy-based instruments. Little is known about which NPS clinicians report and whether their ...

    Authors: Willem S. Eikelboom, Ellen H. Singleton, Esther van den Berg, Casper de Boer, Michiel Coesmans, Jeannette A. Goudzwaard, Everard G. B. Vijverberg, Michel Pan, Cornalijn Gouw, Merel O. Mol, Freek Gillissen, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, John C. van Swieten, Rik Ossenkoppele…
    Citation: Alzheimer's Research & Therapy 2023 15:94
  44. APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers.

    Authors: Lou Grangeon, Camille Charbonnier, Aline Zarea, Stephane Rousseau, Anne Rovelet-Lecrux, David Bendetowicz, Marion Lemaitre, Cécile Malrain, Muriel Quillard-Muraine, Kevin Cassinari, David Maltete, Jeremie Pariente, Olivier Moreaud, Eloi Magnin, Benjamin Cretin, Marie-Anne Mackowiak…
    Citation: Alzheimer's Research & Therapy 2023 15:93
  45. Studies on DNA methylation (DNAm) in Alzheimer’s disease (AD) have recently highlighted several genomic loci showing association with disease onset and progression.

    Authors: Yasmine Sommerer, Valerija Dobricic, Marcel Schilling, Olena Ohlei, Sanaz Sedghpour Sabet, Tanja Wesse, Janina Fuß, Sören Franzenburg, Andre Franke, Laura Parkkinen, Christina M. Lill and Lars Bertram
    Citation: Alzheimer's Research & Therapy 2023 15:92
  46. Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [18F]-flortauc...

    Authors: Julien Lagarde, Pauline Olivieri, Matteo Tonietto, Sébastian Rodrigo, Philippe Gervais, Fabien Caillé, Martin Moussion, Michel Bottlaender and Marie Sarazin
    Citation: Alzheimer's Research & Therapy 2023 15:91
  47. Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...

    Authors: Tobias Gustavsson, Nicole G. Metzendorf, Elin Wik, Sahar Roshanbin, Ulrika Julku, Aikaterini Chourlia, Per Nilsson, Ken G. Andersson, Hanna Laudon, Greta Hultqvist, Stina Syvänen and Dag Sehlin
    Citation: Alzheimer's Research & Therapy 2023 15:90
  48. It is possible to calculate the number of years to the expected clinical onset (YECO) of autosomal-dominant Alzheimer’s disease (adAD). A similar time scale is lacking for sporadic Alzheimer’s disease (sAD). T...

    Authors: Ove Almkvist and Agneta Nordberg
    Citation: Alzheimer's Research & Therapy 2023 15:89
  49. Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...

    Authors: Dylan R. Kirn, Joshua D. Grill, Paul Aisen, Karin Ernstrom, Seth Gale, Judith Heidebrink, Gregory Jicha, Gustavo Jimenez-Maggiora, Leigh Johnson, Elaine Peskind, Kelly McCann, Elizabeth Shaffer, David Sultzer, Shunran Wang, Reisa Sperling and Rema Raman
    Citation: Alzheimer's Research & Therapy 2023 15:88
  50. Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment.

    Authors: Victoire Leroy, Wassim Gana, Amal Aïdoud, Jacques-Alexis N’kodo, Anna-Chloé Balageas, Pascal Blanc, Dominique Bomia, Camille Debacq and Bertrand Fougère
    Citation: Alzheimer's Research & Therapy 2023 15:87